$BVS News

Transcript: Bioventus Q1 2026 Earnings Conference Call

Bioventus Says FDA Reclassifies Exogen Ultrasound Bone Healing System To Class II Device On April 16, 2026; CMS Updates Medicare Fee Schedule For Non-Invasive Bone Growth Stimulators Effective May 18, 2026; Does Not Expect Material Impact From Exogen Reimbursement Changes In FY26; Reiterates 2026 Financial Guidance - SEC Filing

Is Bioventus (BVS) Stock Undervalued Right Now?

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Bioventus' (NASDAQ:BVS) Solid Earnings Are Supported By Other Strong Factors

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?

Bioventus Inc. Q1 2026 Earnings Call Summary

Bioventus (BVS) Q1 2026 Earnings Transcript

Bioventus Q1 Earnings Call Highlights

Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates

Bioventus Inc (NASDAQ:BVS) Smashes Q1 Estimates and Lifts Guidance, Shares Rally

Bioventus Inc. 2026 Q1 - Results - Earnings Call Presentation

Bioventus Reports First Quarter Financial Results

Bioventus Raises FY2026 Adj EPS Guidance from $0.73-$0.77 to $0.75-$0.79 vs $0.75 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.747M Est

Bioventus Q1 Adj. EPS $0.15 Beats $0.10 Estimate, Sales $132.089M Beat $129.850M Estimate

Should Value Investors Buy Bioventus (BVS) Stock?

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

Strength Seen in Bioventus (BVS): Can Its 6.6% Jump Turn into More Strength?

Are Investors Undervaluing Bioventus (BVS) Right Now?